Lip Gregory Y H, Apostolakis Stavros
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, UK.
BMJ Clin Evid. 2011 Feb 15;2011:0210.
Acute atrial fibrillation is rapid, irregular, and chaotic atrial activity of less than 48 hours' duration. Risk factors for acute atrial fibrillation include increasing age, cardiovascular disease, alcohol, diabetes, and lung disease. Acute atrial fibrillation increases the risk of stroke and heart failure. The condition resolves spontaneously within 24 to 48 hours in over 50% of people; however, many people will require interventions to control heart rate or restore sinus rhythm.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent embolism, for conversion to sinus rhythm, and to control heart rate in people with recent-onset atrial fibrillation (within 7 days) who are haemodynamically stable? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 30 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: amiodarone, antithrombotic treatment before cardioversion, digoxin, diltiazem, direct current cardioversion, flecainide, propafenone, quinidine, sotalol, timolol, and verapamil.
急性心房颤动是指持续时间少于48小时的快速、不规则且紊乱的心房活动。急性心房颤动的危险因素包括年龄增长、心血管疾病、酒精、糖尿病和肺部疾病。急性心房颤动会增加中风和心力衰竭的风险。超过50%的患者在24至48小时内可自行缓解;然而,许多患者需要干预措施来控制心率或恢复窦性心律。
我们进行了一项系统评价,旨在回答以下临床问题:对于血流动力学稳定的近期发作心房颤动(7天内)患者,预防栓塞、转复窦性心律以及控制心率的干预措施有哪些效果?我们检索了:截至2010年4月的医学期刊数据库(Medline)、荷兰医学文摘数据库(Embase)、考克兰图书馆以及其他重要数据库(《临床证据》综述会定期更新;请查看我们的网站获取本综述的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品及医疗产品监管局(MHRA)等相关组织的危害警示。
我们找到了30项符合我们纳入标准的系统评价、随机对照试验或观察性研究。我们对干预措施证据的质量进行了GRADE评估。
在本系统评价中,我们提供了以下干预措施的有效性和安全性相关信息:胺碘酮、复律前抗栓治疗、地高辛、地尔硫䓬、直流电复律、氟卡尼、普罗帕酮、奎尼丁、索他洛尔、噻吗洛尔和维拉帕米。